INDV — Indivior Pharmaceuticals Inc

Summary of Indivior Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenue: $317 million, up 19% year-over-year.
• SUBLOCADE Net Revenue: $232 million, a 32% increase year-over-year, with U.S. sales growing 33%.
• Adjusted EBITDA: $164 million, up 112% year-over-year, with a margin improvement of 23 percentage points to 51%.
• Gross Cash and Investments: $201 million.
• Debt Management: Issued $500 million in convertible notes, reducing interest rate from 9.5% to 0.625%.
• Share Repurchase: $125 million spent on repurchasing shares at an average price of $31.45.

2. Strategic Updates and Business Highlights

• Phase II - Accelerate of the Indivior Action Agenda is focused on enhancing SUBLOCADE's growth and improving commercial execution.
• New Patient Starts: Achieved record new patient starts for SUBLOCADE at approximately 31,800, a 29% increase year-over-year.
• Consumer Campaign: The "Move Forward in Recovery" campaign is driving patient activation and engagement, contributing to SUBLOCADE's growth.
• Commercial Strategy: Enhanced service agreements with specialty pharmacies have improved dispense yields.
• R&D Pipeline Update: INDV-6001 will not proceed to Phase III, and INDV-2000 did not meet primary endpoints in trials, leading to a shift in focus towards external business development opportunities.

3. Forward Guidance and Outlook

• 2026 Financial Guidance: Total net revenue expected to be between $1.215 billion and $1.285 billion, with SUBLOCADE net revenue projected at $950 million to $990 million (13% growth).
• Adjusted EBITDA Guidance: Expected to be between $620 million and $660 million, a 50% increase year-over-year.
• Dispense Unit Growth: Anticipated to reach mid-teens growth for SUBLOCADE in 2026, up from 7% in 2025.

4. Bad News, Challenges, or Points of Concern

• R&D Setbacks: INDV-6001 and INDV-2000 will not advance, which may impact future growth and innovation.
• Gross-to-Net Adjustments: Expected to serve as a headwind for both SUBLOCADE and SUBOXONE in 2026.
• Market Competition: Potential competition from new entrants like Lilly's brenipatide could impact SUBLOCADE's long-term growth, although the company maintains confidence in its differentiated profile.

5. Notable Q&A Insights

• Gross Margins: Expected to remain in the mid-80% range, with Q1 benefiting from prior year releases and positive manufacturing variances.
• Business Development Focus: Indivior is looking for commercial stage assets with potential peak sales over $200 million and is open to acquiring companies with pipelines if they align with strategic goals.
• Patient Persistence: The accelerated second dosing of SUBLOCADE is believed to improve early patient stabilization and may enhance long-term persistence in treatment.
• LAI Category Growth: The long-acting injectable (LAI) category is growing, with SUBLOCADE maintaining a stable market share of 76%.

Overall, Indivior's Q1 2026 results reflect strong financial performance driven by SUBLOCADE, strategic initiatives to enhance growth, and a cautious but optimistic outlook for the remainder of the year despite challenges in R&D and potential market competition.